Novo Nordisk reported DKK4.44B in Ordinary Share Capital for its fiscal quarter ending in December of 2025.





Ordinary Share Capital Change Date
Bausch Health Companies USD 373.46M 2.93M Mar/2026
Bristol-Myers Squibb USD 2.04B 1.74B Sep/2025
Eli Lilly USD 943.5M 3.33M Mar/2026
GlaxoSmithKline GBP 4.05B 20.6M Mar/2026
Merck USD 2.47B 12.72M Dec/2025
Novartis USD 1.91B 60K Mar/2026
Novo Nordisk DKK 4.44B 0 Dec/2025
Novo Nordisk DKK 4.44B 3.99B Jun/2025
Pacira USD 39.31M 1.81M Mar/2026
Sanofi EUR 1.21B 8.25M Mar/2026
Supernus Pharmaceuticals USD 58.04M 582K Mar/2026